½ÃÀ庸°í¼­
»óǰÄÚµå
1495947

µÎ°³³» µ¿¸Æ·ù ½ÃÀå - ¿¹Ãø(2024-2029³â)

Intracranial Aneurysm Market - Forecasts from 2024 to 2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Knowledge Sourcing Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 146 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

µÎ°³³» µ¿¸Æ·ù ½ÃÀåÀº ¿¬Æò±Õ 8.41% ¼ºÀåÇÏ¿© 2022³â 14¾ï 1,100¸¸ ´Þ·¯¿¡¼­ 2029³â 24¾ï 8,400¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

³úµ¿¸Æ·ù´Â ³úÀÇ Ç÷¾× µ¿¸Æ º®ÀÇ ¾àÇÑ ºÎºÐ¿¡¼­ ¹ß»ýÇϴ dz¼± °°Àº °ÍÀÔ´Ï´Ù(³úµ¿¸Æ·ù ¶Ç´Â µÎ°³ ³» µ¿¸Æ·ù¶ó°íµµ ÇÔ). ³ú ÁÖº¯À¸·Î ÃâÇ÷ÇÏ´Â ÁöÁÖ¸·ÇÏ ÃâÇ÷(SAH)Àº µ¿¸ÆÀÌ "¹°Áýó·³" È®ÀåµÇ¾î µ¿¸ÆÀÌ ¾ã¾ÆÁö°í °©ÀÚ±â ÅÍÁö¸é¼­ ¹ß»ýÇÕ´Ï´Ù.

ÀÌ·¯ÇÑ ÃâÇ÷Àº ³úÁ¹Áß, ÀÇ½Ä Àå¾Ö, ½ÉÁö¾î »ç¸Á¿¡ À̸¦ ¼öµµ ÀÖ½À´Ï´Ù. µ¿¸Æ·ùÀÇ Å©±â´Â 1/8ÀÎÄ¡¿¡¼­ 1ÀÎÄ¡±îÁö ´Ù¾çÇÕ´Ï´Ù. °Å´ë µ¿¸Æ·ù´Â Ä¡·á°¡ ¾î·Æ°í, ƯÈ÷ 1ÀÎÄ¡¸¦ ÃʰúÇÏ´Â °æ¿ì ½É°¢ÇÑ À§ÇèÀ» ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù.

µÎ°³³» µ¿¸Æ·ù ½ÃÀåÀÇ ¼ºÀå ±âȸ

³úµ¿¸Æ·ù À¯º´·üÀº ¿¹Ãø ±â°£ µ¿¾È Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÃÖ¼Òħ½ÀÀû µÎ°³³» µ¿¸Æ·ù ¼ö¼úÀÌ µÎ°³³» µ¿¸Æ·ù »ê¾÷¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µÎ°³³» µ¿¸Æ·ù´Â ³úµ¿¸ÆÀÇ º®ÀÌ ºÎÇ®¾î ¿À¸£´Â ÁúȯÀÔ´Ï´Ù. ºÎÀÚ¿¬½º·´°Ô ºÎÇ®¾î ¿À¸£°í, ÆÛÁö°í, ÃâÇ÷À» ÀÏÀ¸Åµ´Ï´Ù.

³úµ¿¸Æ·ù ¹ß»ýÀÇ À§ÇèÀÎÀڷδ Èí¿¬, °íÇ÷¾Ð, Ç÷°ü ¿Ü»ó, À¯ÀüÀû Ãë¾à¼º, Ç÷°ü ¼Õ»ó µîÀÌ ÀÖ½À´Ï´Ù. ³úµ¿¸Æ·ù Ä¡·á´Â ³»°úÀû Ä¡·á, ¿Ü°úÀû Ŭ¸®Çμú, Ç÷°ü ³» Ä¡·á, ÄÚÀϸµ ´Üµ¶ ¶Ç´Â º¸Á¶±â±¸¿Í ÇÔ²² ½ÃÇàµË´Ï´Ù.

°í·É Àα¸ Áõ°¡

µÎ°³³» µ¿¸Æ·ù ½ÃÀåÀº Ç÷°ü ¿Ü»ó ¹× °úµµÇÑ Ç÷¾ÐÀ» °¡Áø ȯÀÚÀÇ Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °íÇ÷¾ÐÀº ³úµ¿¸Æ·ù¸¦ Æ÷ÇÔÇÑ ¿©·¯ Áúº´ÀÇ À§ÇèÀ» Å©°Ô Áõ°¡½Ãŵ´Ï´Ù. Àα¸ÀÇ »ó´ç ºÎºÐÀÌ °úµµÇÑ Ç÷¾Ð°ú Èí¿¬À¸·Î ÀÎÇØ ³úµ¿¸Æ·ù°¡ ¹ß»ýÇÒ À§ÇèÀÌ ÀÖ½À´Ï´Ù.

NCBIÀÇ Á¶»ç °á°ú¿¡ µû¸£¸é ³ëÀÎÀÇ ¹ÌÆÄ¿­ ³úµ¿¸Æ·ù À¯º´·üÀÌ ºü¸£°Ô Áõ°¡Çϰí ÀÖÀ¸¸ç, ƯÈ÷ 70¼¼ ÀÌ»ó ³ëÀο¡¼­ µÎµå·¯Áö¸ç, WHO º¸°í¼­ 2022¿¡ µû¸£¸é, 2050³â±îÁö 60¼¼ ÀÌ»ó ³ëÀÎÀº Àü ¼¼°èÀûÀ¸·Î 35¾ï ¸íÀ¸·Î 2019³â 10¾ï ¸í¿¡¼­ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÃÖ¼Òħ½À ¼ö¼úÀÇ Áõ°¡

ÃÖ±Ù ÃÖ¼Òħ½À ¼ö¼úÀº À§Çè°ú ¿Ü»óÀÌ Àû±â ¶§¹®¿¡ Á¡Á¡ ´õ º¸ÆíÈ­µÇ°í ÀÖ½À´Ï´Ù. Àý°³Ã¢À» ÀÛ°ÔÇÔÀ¸·Î½á ¼ö¼ú ÈÄ ºÒÆíÇÔÀ» ÁÙÀ̰í Ä¡À¯¸¦ ¾Õ´ç±æ ¼ö Àֱ⠶§¹®¿¡ ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ º¸±ÞÀ» ÃËÁøÇϰí ÀÌ ºÐ¾ßÀÇ ¿¬±¸ ¹× °³¹ßÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÃÖ÷´Ü ÃÖ¼Òħ½ÀÀû Ç÷°ü ³» ÄÚÀϸµ µµ±¸¸¦ µµÀÔÇϱâ À§ÇØ ÀϺΠÁÖ¿ä ÁøÀÔ ±â¾÷µéÀº Áö¼ÓÀûÀ¸·Î ¿¬±¸°³¹ß¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÀÇ»çµéÀÌ °­·ÂÈ÷ ÃßõÇÏ´Â ÃÖ¼Òħ½ÀÀû Ä¡·á¹ý Áß Çϳª´Â ³úµ¿¸Æ·ù Ä¡·á¿¡ »ç¿ëµÇ´Â Ç÷°ü ³» ÄÚÀϸµÀÔ´Ï´Ù. ÀÌ ¼ö¼úÀº ¹Ì¼¼ Ä«Å×Å͸¦ µ¿¸Æ·ù°¡ ÀÖ´Â ³úµ¿¸Æ¿¡ µ¿¸Æ·ù°¡ ÀÖ´Â ºÎÀ§ÀÇ µ¿¸Æ¿¡ »ðÀÔÇÏ´Â ¼ö¼úÀÔ´Ï´Ù. ±× ÈÄ ¹é±Ý ÄÚÀÏÀ» Á¦°ÅÇÕ´Ï´Ù. ¹é±Ý ÄÚÀÏÀº µ¿¸Æ·ù°¡ ÀÀ°íµÇ¾î ³úÀÇ ´Ù¸¥ ºÎºÐÀ¸·Î °¡´Â Ç÷·ù¸¦ Â÷´ÜÇϱ⠶§¹®ÀÔ´Ï´Ù.

Ç÷°ü ³» ÄÚÀϸµÀº ÃßÁø·Â ÀÖ´Â ºÎ¹®

ÇâÈÄ Ç÷°ü ³» ÄÚÀϸµÀº ²ÙÁØÈ÷ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ¼ö¼úÀÇ ÀåÁ¡Àº ôÃß ³úÀú°è¿¡ ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ´Ù´Â Á¡, ¿ø°ÝÁö¿¡ ÀÖ´Â ¸¹Àº µ¿¸Æ·ù, ´Ù¸¥ ¼ö¼úº¸´Ù ºü¸¥ ȸº¹ ±â°£ µîÀÌ µÎ°³³» µ¿¸Æ·ù ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Àü ¼¼°èÀûÀ¸·Î Áõ°¡ÇÏ´Â ³úÁ¹ÁßÀ¸·Î ÀÎÇØ Ç÷°üÀÌ ÆÄ¿­µÇ¾î ³úµ¿¸Æ·ù°¡ ¹ß»ýÇÒ °¡´É¼ºÀÌ ³ôÀ¸¸ç, ÀÌ´Â µÎ°³³» µ¿¸Æ·ù ½ÃÀåÀÇ ¼öÀÍ È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ¼¼°è³úÁ¹Á߱ⱸ(WSO)´Â 2022³â±îÁö ¾à 1,200¸¸ ¸í(1,224¸¸ 4,551¸í)ÀÌ ³úÁ¹ÁßÀ» ¾ÎÀ» °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù.

¿¬±¸ °³¹ß ¹× ±â¼ú Çõ½ÅÀÇ Áõ°¡

µÎ°³³» µ¿¸Æ·ù Ä¡·á¸¦ À§ÇÑ ¿¬±¸°³¹ßÀÇ Áõ°¡, ÀÇ·á ½Ã¼³ÀÇ °³¼±, µÎ°³³» µ¿¸Æ·ù Áø´Ü ¹× Ä¡·áÀÇ ±â¼úÀû Áøº¸, ¾÷°èÀÇ ¿¬±¸°³¹ß ¼ºÀå, ÀÏ»óÀûÀÎ ÀÇ·á ÅõÀÚ Áõ°¡·Î ÀÎÇØ µÎ°³³» µ¿¸Æ·ù »ê¾÷Àº ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ °æÇèÇÏ°Ô µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¹¸¦ µé¾î, ¾Æ¼¼Æ¿»ì¸®½Ç»ê°ú Àû±ØÀûÀÎ Ç÷¾Ð °ü¸®ÀÇ º´¿ëÀº ±«Å×´ëÇÐ ½Å°æ°ú ¹× ½Å°æ¿Ü°ú¿¡¼­ ¹ÌÆÄ¿­ ³úµ¿¸Æ·ù ȯÀÚ¸¦ ´ë»óÀ¸·Î 3»ó Àӻ󿬱¸°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

µÎ°³³» µ¿¸Æ·ù ½ÃÀåÀ» Áö¿øÇÏ´Â ¿µ»ó Áø´Ü ±â¼ú »ç¿ë Áõ°¡

³úµ¿¸Æ·ù Áø´ÜÀº ÀÚ±â°ø¸íÇ÷°üÁ¶¿µ¼ú(MRA), ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(CTA), µ¿¸Æ³» µðÁöÅÐ ¼­ºêÆ®·¢¼Ç Ç÷°üÁ¶¿µ¼ú(IADSA)ÀÇ ¼¼ °¡Áö ¿µ»óÁø´Ü¹ý¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖÀ¸¸ç, CTA´Â ±âÁ¸ÀÇ Ç÷°üÁ¶¿µ¼ú°ú´Â ´Ù¸¥ Ç÷°üÁ¶¿µ¼ú·Î, Á¶¿µÁ¦¸¦ Á¤¸ÆÁÖ»çÇϸ鼭 ÀÏ¹Ý CT ½ºÄµÀ» ÇÕ´Ï´Ù.

ÇöÀç µÎ°³³» µ¿¸Æ·ù ½Äº°À» À§ÇÑ Ç¥ÁØÀº IADSAÀÔ´Ï´Ù. ¶ÇÇÑ, °³¾÷ÀǵéÀº µ¿¸Æ ³» µðÁöÅÐ º¸Á¶ Ç÷°ü Á¶¿µ¼úÀ» »ç¿ëÇÏ¿© µÎ°³³» µ¿¸Æ·ù ȯÀÚ¸¦ Ä¡·áÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ µÎ°³³» µ¿¸Æ·ù ½ÃÀåÀ» ÁÖµµÇÏ´Â ÀÌÀ¯ Áß Çϳª´Â µÎ°³³» µ¿¸Æ·ù Ä¡·á¸¦ À§ÇÑ ¿ì¼öÇÑ ¿µ»óÀ» Á¦°øÇÏ´Â ¿µ»ó ±â¹ýÀÔ´Ï´Ù.

ºÏ¹Ì µÎ°³³» µ¿¸Æ·ù ½ÃÀåÀÌ ÁÖµµÇÒ °ÍÀ¸·Î Àü¸Á

ºÏ¹Ì´Â źźÇÑ ÀÇ·á ÀÎÇÁ¶ó, °í·ÉÈ­, ³ôÀº °íÇ÷¾Ð ¹× ³úÁ¹Áß ¹ß»ý·ü·Î ÀÎÇØ µÎ°³³» µ¿¸Æ·ù ½ÃÀåÀ» ¼±µµÇϸç Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, ³úµ¿¸Æ·ù ¹ß»ý·üÀÇ Áõ°¡¿Í ´ú ħ½ÀÀûÀÎ ½Ã¼úÀÇ Çʿ伺ÀÌ ÀÌ Áö¿ªÀÇ µÎ°³³» µ¿¸Æ·ù ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ ´ÜüÀÇ ÇÁ·ÎÁ§Æ® Áõ°¡µµ µÎ°³³» µ¿¸Æ·ù ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, The Bee Foundation(TBF)Àº ÃÖ÷´Ü ¿¬±¸¸¦ ÅëÇØ ³úµ¿¸Æ·ù·Î ÀÎÇÑ »ç¸ÁÀÚ ¼ö¸¦ ÁÙÀ̱â À§ÇØ ÀÎ½Ä °³¼±¿¡ Èû¾²°í ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº Á¦2ÀÇ ¼ºÀå ½ÃÀåÀ¸·Î ºÎ»óÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ µÎ°³³» µ¿¸Æ·ù »ê¾÷Àº ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±× ¹è°æ¿¡´Â Àα¸ °í·ÉÈ­, ´Ù¾çÇÑ »ýȰ½À°ü ½ºÆ®·¹½º ¿äÀÎ, °íÇ÷¾Ð À¯º´·ü Áõ°¡, Áø´ÜÀÇ ÁúÀû Çâ»ó, ȯÀÚ ºÎ´ã °¨¼Ò µîÀÌ ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â ¾Õ¼­ ¾ð±ÞÇÑ ¸ðµç º¯¼öÀÇ °á°ú·Î ³úµ¿¸Æ·ù ¼ö¼úÀÌ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áß±¹, Àεµ, ÀϺ»°ú °°Àº ½ÅÈï±¹ÀÇ ¸Å·ÂÀûÀÎ ½ÃÀå °³¹ß Àü¸ÁÀº ÀÌ Áö¿ªÀÇ µÎ°³³» µ¿¸Æ·ù ½ÃÀå È®´ë¿¡ ±â¿©ÇßÀ» °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹°ú °°Àº ¼±Áø±¹¿¡ ºñÇØ »ó´ëÀûÀ¸·Î Àú·ÅÇÑ µÎ°³³» ¼ö¼ú ºñ¿ëÀ¸·Î ÀÎÇØ Àεµ¿¡ ´ëÇÑ ÀÇ·á°ü±¤°´ÀÇ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

  • ½ÃÀå °³¿ä
  • ½ÃÀå Á¤ÀÇ
  • Á¶»ç ¹üÀ§
  • ½ÃÀå ¼¼ºÐÈ­
  • ÅëÈ­
  • °¡Á¤
  • ±âÁØ ¿¬µµ¿Í ¿¹Ãø ¿¬µµ ŸÀÓ¶óÀÎ
  • ÀÌÇØ°ü°èÀÚ¿¡ ´ëÇÑ ÁÖ¿ä ÀÌÁ¡

Á¦2Àå Á¶»ç ¹æ¹ý

  • Á¶»ç µðÀÚÀÎ
  • Á¶»ç °úÁ¤

Á¦3Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • Porter's Five Forces ºÐ¼®
  • ¾÷°è ¹ë·ùüÀÎ ºÐ¼®
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ

Á¦5Àå µÎ°³³» µ¿¸Æ·ù ½ÃÀå : À¯Çüº°

  • ¼Ò°³
  • ¿Ü°úÀû Ŭ¸®ÇÎ
  • Ç÷°ü³» ÄÚÀÏ »öÀü¼ú
  • ÇÃ·Î¿ì ´ÙÀ̹öÅÍ
  • ±âŸ

Á¦6Àå µÎ°³³» µ¿¸Æ·ù ½ÃÀå : Áø´Ü À¯Çüº°

  • ¼Ò°³
  • CT ½ºÄµ
  • MRI
  • ³ú Ç÷°üÁ¶¿µ ½ÃÇè
  • ³úô¼ö¾×(CSF) ºÐ¼®

Á¦7Àå µÎ°³³» µ¿¸Æ·ù ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼Ò°³
  • º´¿ø
  • Ŭ¸®´Ð
  • ±âŸ

Á¦8Àå µÎ°³³» µ¿¸Æ·ù ½ÃÀå : Áö¿ªº°

  • ¼Ò°³
  • ºÏ¹Ì
  • ³²¹Ì
  • À¯·´
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦9Àå °æÀï ȯ°æ°ú ºÐ¼®

  • ÁÖ¿ä ±â¾÷°ú Àü·« ºÐ¼®
  • ½ÃÀå Á¡À¯À² ºÐ¼®
  • ÇÕº´, Àμö, ÇÕÀÇ¿Í Çù¾÷
  • °æÀï ´ë½Ãº¸µå

Á¦10Àå ±â¾÷ °³¿ä

  • Mayo Clinic
  • Terumo
  • Medtronic
  • Kaneka
  • Johns Hopkins Medicine
  • Lepu Medical Technology Company
  • Philips
  • Mayfield Clinic
  • J&J MedTech
ksm 24.06.24

The intracranial aneurysm market is expected to grow at a CAGR of 8.41% from US$1.411 billion in 2022 to US$2.484 billion in 2029.

A brain aneurysm is a ballooning that develops from a weak spot in the wall of a blood artery in the brain (also known as a cerebral aneurysm or an intracranial aneurysm). A subarachnoid hemorrhage (SAH), which causes bleeding into the area around the brain, occurs when the artery develops a "blister-like" dilatation that can thin out and burst suddenly.

Such a hemorrhage may result in a stroke, unconsciousness, or even death. Aneurysms can be anything from a little 1/8 inch and about one inch in size. Giant aneurysms are difficult to cure and pose a particularly significant danger if they are greater than one inch.

Market growth opportunities for the intracranial aneurysm market

The prevalence of brain aneurysms is expected to increase over the forecast period, and minimally invasive intracranial aneurysm surgeries are expected to be used more frequently fueling the intracranial aneurysm industry. A cerebral artery's wall bulges due to an intracranial aneurysm. An unnatural inflating, widening, or bleb is the outcome.

Risk factors for the occurrence of a brain aneurysm include smoking, hypertension, blood vessel trauma, hereditary vulnerability, and blood vessel damage. Brain aneurysms may be treated with medical therapy, surgical clipping, endovascular therapy, or coiling alone or in combination with auxiliary devices.

Growing geriatric population

The intracranial aneurysm market is being driven by the rising number of patients who have blood vessel trauma and excessive blood pressure. Hypertension significantly raises the risk of several disorders, including brain aneurysms. A significant section of the population is in danger of developing brain aneurysms because of excessive blood pressure and smoking.

Unruptured brain aneurysm prevalence in senior people is rising quickly, especially in those who are 70 years or older, according to NCBI research findings. According to the WHO Report 2022, there will be 3.5 billion people in the globe who are 60 years of age or older by 2050, up from 1 billion in 2019.

Growth in the use of minimally invasive surgeries

Minimally invasive operations are becoming common nowadays due to their lower risk and trauma. Smaller incisions reduce postoperative discomfort and speed up healing, which encourages the widespread use of these treatments and spurs an increase in R&D in the area.

To introduce cutting-edge minimally invasive endovascular coiling tools, several important players are consistently investing in R&D. One of the less invasive treatments that is strongly advised by doctors is the endovascular coiling used to treat cerebral aneurysms. A microcatheter is placed during this surgery through the aneurysm-containing artery in the groyne region. After that, platinum coils are removed since they encourage aneurysm clotting and stop blood flow to other parts of the brain.

Endovascular coiling is a propelling sector

The future is expected to see steady growth for endovascular coiling. The benefits of this operation, including simple access to the vertebrobasilar system, numerous aneurysms in remote locations, and a quicker recovery period than with other procedures, are the reasons driving the intracranial aneurysm market expansion.

Additionally, there is a strong likelihood that the increasing number of strokes occurring globally would rupture blood vessels and cause cerebral aneurysms, which will encourage intracranial aneurysm market revenue growth. For instance, the World Stroke Organization (WSO) reported that in 2022, around 12 million (12,224,551) persons suffered from a stroke.

Growing research and development and technological breakthroughs

With the rise in research and development for the treatment of intracranial aneurysms, improved healthcare facilities, technological advancements in the diagnosis of intracranial aneurysms and the treatment with novel therapeutics, growing research and development in the industry as well as daily increases in healthcare investment, the intracranial aneurysm industry will experience lucrative growth opportunities in the forecast period.

For instance, Acetylsalicylic acid combined with aggressive blood pressure management is being studied in phase 3 clinical investigation at Goethe University's Department of Neurology and Neurosurgery in patients with unruptured cerebral aneurysms.

Increasing the use of imaging techniques to assist the intracranial aneurysm market

The diagnosis of cerebral aneurysms relies heavily on three imaging modalities, magnetic resonance angiography (MRA), computed tomography (CTA), and intra-arterial digital subtraction angiography (IADSA). CTA is a different vascular imaging technique that includes getting a conventional CT scan while receiving an intravenous contrast injection.

The gold standard for identifying intracranial aneurysms at the moment is IADSA. Additionally, medical practitioners use intra-arterial digital subtraction angiography to treat intracranial aneurysm patients. Therefore, one of the reasons propelling the intracranial aneurysm market is imaging modalities that offer superior pictures for the treatment of intracranial aneurysms.

The North American intracranial aneurysm market is projected to propel

North America is anticipated to lead the intracranial aneurysm market and account for a large revenue share due to its established healthcare infrastructure, ageing population, and high rates of hypertension and stroke.

Additionally, a rise in the incidence of cerebral aneurysms and a need for less invasive procedures are fueling intracranial aneurysm market expansion in the area. An increasing number of projects being carried out by various groups is also projected to encourage intracranial aneurysm market expansion. For instance, The Bee Foundation (TBF) is committed to raising awareness and lowering the number of fatalities brought on by brain aneurysms via cutting-edge studies.

Asia Pacific is anticipated to be the second-largest growing market

The Asia Pacific intracranial aneurysm industry is anticipated to grow. This is due to several causes, including an ageing population, numerous lifestyle stressors, an increase in the prevalence of hypertension, better diagnostic quality, and increased patient affordability.

The Asia Pacific region has seen a large increase in cerebral aneurysm surgeries as a result of all the aforementioned variables. Moreover, the expansion of the regional intracranial aneurysm market is likely aided by attractive development prospects in emerging nations like China, India, and Japan. For instance, rising medical tourism to India is anticipated to boost the market because of the comparatively inexpensive cost of intracranial surgery compared to other industrialized nations like the U.S.

Market Key Developments

  • In June 2023, researchers at the RIKEN Centre for Brain Science (CBS) in Japan identified a group of linked mutations that cause intracranial aneurysms weakened blood arteries in the brain that are prone to rupture at any time.
  • In September 2022, Vesalio announced that the NeVa VS has been approved by the Food and Drug Administration to treat cerebral vasospasm following aneurysmal rupture.
  • In June 2022, the first Numen coil embolization treatment and portfolio expansion by Rapid Medical were announced. Rapid Medical and MicroPort NeuroTech, a division of MicroPort Scientific Corporation, have an exclusive distribution arrangement.

Segmentation:

By Type

  • Surgical Clipping
  • Endovascular Coiling
  • Flow Diverters
  • Others

By Diagnosis Type

  • CT scan
  • MRI
  • Cerebral Angiography
  • Cerebrospinal Fluid (CSF) Analysis

By End-User

  • Hospitals
  • Clinics
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits for the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. INTRACRANIAL ANEURYSM MARKET, BY TYPE

  • 5.1. Introduction
  • 5.2. Surgical Clipping
    • 5.2.1. Market Trends and Opportunities
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Endovascular Coiling
    • 5.3.1. Market Trends and Opportunities
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Flow Diverters
    • 5.4.1. Market Trends and Opportunities
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Trends and Opportunities
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. INTRACRANIAL ANEURYSM MARKET, BY DIAGNOSIS TYPE

  • 6.1. Introduction
  • 6.2. CT scan
    • 6.2.1. Market Trends and Opportunities
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. MRI
    • 6.3.1. Market Trends and Opportunities
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Cerebral Angiography
    • 6.4.1. Market Trends and Opportunities
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Cerebrospinal Fluid (CSF) Analysis
    • 6.5.1. Market Trends and Opportunities
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness

7. INTRACRANIAL ANEURYSM MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
    • 7.2.1. Market Trends and Opportunities
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Clinics
    • 7.3.1. Market Trends and Opportunities
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Others
    • 7.4.1. Market Trends and Opportunities
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. INTRACRANIAL ANEURYSM MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Diagnosis Type
    • 8.2.3. By End Users
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Trends and Opportunities
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Trends and Opportunities
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Trends and Opportunities
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Diagnosis Type
    • 8.3.3. By End Users
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Trends and Opportunities
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Trends and Opportunities
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Trends and Opportunities
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Diagnosis Type
    • 8.4.3. By End Users
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Trends and Opportunities
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Trends and Opportunities
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1. Market Trends and Opportunities
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Spain
        • 8.4.4.4.1. Market Trends and Opportunities
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Trends and Opportunities
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Diagnosis Type
    • 8.5.3. By End Users
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Trends and Opportunities
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Trends and Opportunities
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Trends and Opportunities
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Trends and Opportunities
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Diagnosis Type
    • 8.6.3. By End Users
    • 8.6.4. By Country
      • 8.6.4.1. Japan
        • 8.6.4.1.1. Market Trends and Opportunities
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. China
        • 8.6.4.2.1. Market Trends and Opportunities
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Trends and Opportunities
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Trends and Opportunities
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Indonesia
        • 8.6.4.5.1. Market Trends and Opportunities
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Trends and Opportunities
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Others
        • 8.6.4.7.1. Market Trends and Opportunities
        • 8.6.4.7.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Mayo Clinic
  • 10.2. Terumo
  • 10.3. Medtronic
  • 10.4. Kaneka
  • 10.5. Johns Hopkins Medicine
  • 10.6. Lepu Medical Technology Company
  • 10.7. Philips
  • 10.8. Mayfield Clinic
  • 10.9. J&J MedTech
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦